Stock Research: ClearPoint Neuro

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

ClearPoint Neuro

NasdaqCM:CLPT US18507C1036
19
  • Value
    14
  • Growth
    69
  • Safety
    Safety
    8
  • Combined
    6
  • Sentiment
    20
  • 360° View
    360° View
    19
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company focused on precise navigation to the brain and spine, providing clinical products and pre-clinical development services for controlled drug and device delivery. Its main business is the ClearPoint Neuro Navigation System and the ClearPoint Prism Neuro Laser Therapy System. The company operates in North America, Europe, Asia, and South America. In the last fiscal year, the company had 115 employees, a market cap of $317 million, profits of $19 million, and revenue of $31 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 19 (better than 19% compared with alternatives), overall professional sentiment and financial characteristics for the stock ClearPoint Neuro are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for ClearPoint Neuro. The consolidated Growth Rank has a good rank of 69, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 69% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 8 means that the share price of ClearPoint Neuro is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 92% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 14, which means that the company has a riskier financing structure than 86% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 20, indicating professional investors are more pessimistic about the stock than for 80% of alternative investment opportunities. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
8 11 24 21
Growth
69 100 23 1
Safety
Safety
14 14 16 20
Sentiment
20 78 78 34
360° View
360° View
19 19 1 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
67 93 93 46
Opinions Change
2 50 50 50
Pro Holdings
n/a 70 55 62
Market Pulse
42 40 59 25
Sentiment
20 78 78 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
8 11 24 21
Growth
69 100 23 1
Safety Safety
14 14 16 20
Combined
6 6 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
40 40 40 40
Price vs. Earnings (P/E)
5 3 30 15
Price vs. Book (P/B)
5 7 19 40
Dividend Yield
1 1 1 1
Value
8 11 24 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
98 85 89 71
Profit Growth
14 73 13 1
Capital Growth
31 84 1 19
Stock Returns
87 100 45 23
Growth
69 100 23 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 61 60 3
Refinancing
11 12 49 69
Liquidity
6 6 6 39
Safety Safety
14 14 16 20

Similar Stocks

Discover high‑ranked alternatives to ClearPoint Neuro and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cigna

NYSE:CI
Country: USA
Industry: Health Care Services
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.